文献速递神经肿瘤

AKT/GSK-3β/β-catenin信号通路参与促红细胞生成素促进的胶质瘤增殖

AKT/GSK-3β/β-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation.
PubMed 文献 · J Neurooncol · 2020-09-09

本研究探讨AKT/GSK-3β/β-catenin通路在EPO介导的胶质瘤增殖中的作用。临床样本显示EPO表达随WHO分级和Ki67升高而增加;体外敲低EPO可阻断AKT/GSK-3β磷酸化及核β-catenin表达,减慢细胞周期并抑制增殖,而rhEPO可逆转此效应,MK-2206则废除rhEPO的促增殖作用。

要点

  • EPO表达随胶质瘤WHO分级和Ki67升高而增加。
  • 敲低EPO抑制AKT/GSK-3β/β-catenin通路及胶质瘤增殖。
  • MK-2206可废除rhEPO诱导的通路激活和促增殖效应。

核心结论

  • AKT/GSK-3β/β-catenin轴是EPO诱导胶质瘤增殖的关键介质。

研究设计与样本

  • 临床样本免疫组化分析EPO与Ki-67在不同WHO级别的分布。
  • U87和U251胶质瘤细胞系分别用shEPO、rhEPO和/或AKT抑制剂MK-2206处理。
  • 检测p-AKT、核β-catenin、cyclin D1和p27kip1表达,分析细胞周期及体内外增殖。

主要发现

  • 临床胶质瘤标本中EPO表达随WHO分级和Ki67增加而显著升高。
  • U87和U251细胞敲低内源性EPO有效阻断AKT和GSK-3β磷酸化及核β-catenin表达。
  • shEPO降低cyclin D1、增加p27kip1表达,减慢细胞周期并减少细胞及小鼠移植瘤增殖。
  • 额外给予rhEPO可逆转shEPO介导的上述生物学效应。
  • MK-2206废除rhEPO诱导的AKT/GSK-3β/β-catenin通路激活和增殖。

临床怎么用

  • 提示EPO可能通过AKT/GSK-3β/β-catenin轴促进胶质瘤增殖,需关注EPO使用对胶质瘤患者的潜在风险。
  • AKT抑制剂MK-2206在实验中可阻断rhEPO的促增殖效应,为联合干预提供实验依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although erythropoietin (EPO) has been proven to significantly promote the proliferation of cancer cells, the mechanism for promoting glioma proliferation is poorly understood. Here, we examined the functional role of the AKT/GSK-3β/β-catenin signaling pathway in the EPO-mediated proliferation of glioma. METHODS: The distribution of EPO and Ki-67 among clinical samples with different WHO grades was plotted by Immunological Histological Chemistry analysis. U87 and U251 glioma cell lines were treated with short hairpin RNA targeting (shEPO), recombinant human erythropoietin (rhEPO) and/or AKT-specific inhibitor (MK-2206). The changes in phosphorylated AKT, nuclear β-catenin, cyclin D1 and p27kip1 expression were detected. Cell cycle distributions and glioma proliferation in vitro and in vivo were analyzed. RESULTS: The expression level of EPO was significantly elevated with the increase of WHO grade and Ki67 in clinical glioma specimens. In vitro, knockdown of endogenous EPO in U87 and U251 cells effectively block the phosphorylation of AKT and GSK-3β and the expression of nuclear β-catenin. shEPO treatment also significantly decreased the expression of cyclin D1 and increased the expression of p27kip1. The cell cycle transition then slowed down and the proliferation of glioma cells or mouse xenograft tumors both decreased. Treatment of cells or tumors with extra rhEPO reversed the above biological effects mediated by shEPO. rhEPO-induced activation of the AKT/GSK-3β/β-catenin pathway and proliferation were abolished by MK-2206. CONCLUSIONS: Our study identified the AKT/GSK-3β/β-catenin axis as a critical mediator of EPO-induced glioma proliferation and further provided a clinically significant dimension to the biology of EPO.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tang Z, Yang G, Wang X, et al. AKT/GSK-3β/β-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation. J Neurooncol. 2020. PMID: 32909117. doi:10.1007/s11060-020-03602-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。